Loading
Whether a drug is taken for a set period (say 12 months) and then stopped even though it is still working, or continued indefinitely until it fails. Fixed-duration gives patients years off treatment; continuous therapy avoids the risk of the cancer regrowing.
The debate is sharpest in CLL, where venetoclax-based regimens for 12-15 months (CLL14, GLOW) compete with indefinite BTK inhibitors, and MRD status at the end of therapy predicts who stays in remission. In CML, treatment-free remission after deep response is established; in myeloma, lenalidomide maintenance is continuous but MRD-guided stopping trials are under way; in metastatic melanoma and lung cancer, immunotherapy is often stopped at two years with durable benefit (KEYNOTE-006, CheckMate 153). Fixed-duration reduces cumulative toxicity and cost and permits retreatment; continuous therapy is simpler to prove in trials because progression-free survival keeps counting.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Venetoclax.
Shares Ibrutinib, Venetoclax, Chronic lymphocytic leukaemia.
Shares Ibrutinib, Venetoclax, Chronic lymphocytic leukaemia.
Shares Ibrutinib, Venetoclax, Chronic lymphocytic leukaemia.
Shares Venetoclax, Chronic lymphocytic leukaemia.
Shares Ibrutinib, Chronic lymphocytic leukaemia.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Ibrutinib, Venetoclax.
Shares Ibrutinib, Chronic lymphocytic leukaemia.